Table 2.
Description of the Evaluated Participants and key Factors in the Characterization.
| Valid n | Classification | n | % | |
|---|---|---|---|---|
| Gender | 80 | Female | 52 | 65.0 |
| Male | 28 | 35.0 | ||
| OT group | 80 | AOT | 26 | 32.5 |
| COT | 54 | 67.5 | ||
| Smoking | 80 | Current | 8 | 10.0 |
| Denied | 66 | 82.5 | ||
| Previous | 6 | 7.5 | ||
| Hospitalization | 78 | No | 76 | 97.4 |
| Yes | 1 | 1.3 | ||
| Yes, ITU | 1 | 1.3 | ||
| Mechanical ventilation during COVID-19 | 78 | No | 77 | 98.7 |
| Yes | 1 | 1.3 | ||
| Partial improvement | 78 | No | 10 | 12.8 |
| Yes | 68 | 87.2 | ||
| Side effect with OT | 80 | No | 62 | 77.5 |
| Yes | 18 | 22.5 | ||
| Subjective improvement | 80 | No | 15 | 18.8 |
| Yes | 65 | 81.3 | ||
| Immunization against COVID-19 | 80 | No | 10 | 12.5 |
| Yes | 70 | 87.5 | ||
| Vaccine manufacturer | 70 | AstraZeneca | 25 | 35.7 |
| Pfizer | 25 | 35.7 | ||
| Coronavac | 19 | 27.1 | ||
| Janssen | 1 | 1.4 | ||
| Vaccine before or after starting treatment | 70 | Before | 48 | 68.6 |
| After | 22 | 31.4 |